Tested different radiation doses for early prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you have early-stage prostate cancer confirmed by biopsy or lab tests
- Your prostate cancer risk is low-risk or favorable intermediate-risk (based on PSA, Gleason score, and biopsy results)
- You’re at least 18 years old and can sign consent to join the study
- You can have the treatment under anesthesia (general, spinal, or local) if needed
- You have not had prior radiation to the prostate or the lower pelvis area covering the prostate
- You are not in a current other drug study, and you don’t have serious uncontrolled health problems (like unstable heart disease or active infection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
This trial studies high-dose radiation (HDR) given after prostate cancer returns only in the prostate/seminal vesicles. It may help by trying to control the cancer when it has not spread elsewhere, using targeted treatment based on MRI and biopsy proof.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
This study is testing a new way of giving radiation for prostate cancer, called ePUHRT, combined with a standard brachytherapy boost (a small radioactive implant placed inside the prostate). It aims to see if this approach is well-tolerated and safe for people with higher-risk prostate cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.